Study of an eye injection for diabetic macular edema
Part of Eyes & vision, Hormones & metabolism clinical trials.
This study tests an investigational drug (PRO-169) given as an eye injection to see if it is safe and whether your immune system reacts to it. It is for people with diabetic macular edema, which is swelling in the back of the eye caused by diabetes that can blur vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have diabetes.
- You must have swelling in the back of the eye (macular edema) that affects your vision.
- You must not have started insulin therapy for the first time in the last 4 months.
- You must not have had an eye injection for diabetes-related vision problems in the last 4 months.
- You must not be taking blood thinners or anti-platelet drugs (like aspirin, clopidogrel, or warfarin) within 10 days of the study.
- You must be willing to use contraception (if you can have children) during the study and for 3 months after the last injection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
This trial tests an experimental medication (BI 1815368) given as an eye injection for people with diabetic macular edema, a condition where fluid builds up in the center of the retina and blurs vision. The study aims to see if this new treatment can reduce swelling and improve vision.
This study tests an experimental eye injection (OLN324) for people with diabetic macular edema, a condition where swelling in the back of the eye causes vision loss. The goal is to see if the injection can improve vision.
This trial tests an eye injection called OLN324 for diabetic macular edema, a condition where fluid builds up in the retina and blurs vision. The treatment aims to improve vision and reduce swelling in the eye.
Hear when a new Immunogenicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.